PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Darifenacin hydrobromide - Overactive bladder (adults)

PAD Profile : Darifenacin hydrobromide - Overactive bladder (adults) Important

Keywords :
OAB, urinary frequency, urge incontinence, LUTS, lower urinary tract symptoms, urinary incontinence, anticholinergics, antimuscarinics
Brand Names Include :
Emselex
Important Information :
Switch to solifenacin recommended (if appropriate)

Traffic Light Status

Status 1 of 1.

Status :
Non Formulary
Formulations :
  • Not Specified
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
NFD1
Comments :

The APC recommend switching darifenacin to solifenacin in appropriate patients.

Documents :

Guidelines

The following guidelines are available for this indication.

Other Drugs

Other Indications

No indications returned.

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
06 March 2024
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The APC supports patients in trialling a treatment break of their overactive bladder medicines.

A "Leaflet for trial of stopping anticholinergics" can be found in the documents section.

05 July 2023
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

Darifenacin is non-formulary.

The APC agreed that darifenacin could be switched to solifenacin or an alternative formulary treatment option if solifenacin is contraindicated:

  • In patients with reduced renal function
  • Patients with CNS adverse effects (confusion, drowsiness, halucinations) 
  • Where there is the potential of interactions at Cytochrome P450 3A4
  • in patients where anticholinergics are contraindicated
  • In patients that require a more potent treatment

See Selection Tool for locally agreed OAB treatments.

Associated BNF Codes

07. Obstetrics, Gynaecology and Urinary-Tract Disorders
07.04.02. Drugs for urinary frequency enuresis and incontinence
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More